Hyperfine, Inc. revenue by segment HYPR

Hyperfine, Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $3.2 million, 81% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Revenue
17
4
4
5
3
3
2
2
4
Product
14
+68.2%
share 85.7%
3
+49.0%
share 81.2%
3
+114.0%
share 83.4%
5
+178.7%
share 91.8%
3
-4.7%
share 84.1%
2
share 78.9%
2
share 71.2%
2
share 75.1%
3
share 83.3%
Services
2
-0.4%
share 14.3%
1
+29.2%
share 18.8%
1
+5.0%
share 16.6%
0
-24.6%
share 8.2%
1
-10.5%
share 15.9%
1
share 21.1%
1
share 28.8%
1
share 24.9%
1
share 16.7%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
HYPR (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Guilford, CT
SEC filer status
, Emerging growth company
SEC CIK
1833769
Former names
HealthCor Catalio Acquisition Corp. (until Dec 22, 2021)

Other Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.